Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications

Jisoo A. Kwon, * Gregory J. Dore, Behzad Hajarizadeh, Maryam Alavi, Heather Valerio, Jason Grebely, Rebecca Guy, Richard T. Gray

Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia

* akwon@kirby.unsw.edu.au

Abstract

Australia was one of the first countries to introduce government-funded unrestricted access to direct-acting antiviral (DAA) therapy, with 88,790 treated since March 2016. However, treatment uptake is declining which could potentially undermine Australia's progress towards the WHO HCV elimination targets. Using mathematical modelling, we updated estimates for those living with chronic HCV in Australia, new cases of decompensated cirrhosis (DC), hepatocellular carcinoma (HCC), and liver-related mortality among the HCV-cured and viraemic populations from 2015 to 2030. We considered various DAA treatment scenarios incorporating annual treatment numbers to 2020, and subsequent uptake per year of 6,790 (pessimistic), 8,100 (intermediate), and 11,310 (optimistic). We incorporated the effects of excess alcohol consumption and reduction in progression to DC and HCC among cirrhosis-cured versus viraemic individuals. At the end of 2020, we estimated 117,810 Australians were living with chronic HCV. New cases per year of DC, HCC, and liver-related mortality among the HCV viraemic population decreased rapidly from 2015 (almost eliminated by 2030). In contrast, the growing population size of those cured with advanced liver disease meant DC, HCC, and liver-related mortality declined slowly. The estimated reduction in liver-related mortality from 2015 to 2030 in the combined HCV viraemic and cured population is 25% in the intermediate scenario. With declining HCV treatment uptake and ongoing individual-level risk of advanced liver disease complications, including among cirrhosis-cured individuals, Australia is unlikely to achieve all WHO HCV elimination targets by 2030.

Introduction

Chronic hepatitis C virus (HCV) infection is a global public health threat with 58 million people living with HCV [1], and an estimated 0.29 million liver-related deaths each year, from liver failure and liver cancer [1]. In 2015, the World Health Organization (WHO) set global
targets to eliminate HCV as a major global public health threat by 2030 [2], including three specific targets: 80% of people with HCV treated, and declines in new HCV infections by 90%, and liver-related mortality by 65%. Australia was one of the first countries to introduce government-funded unrestricted access to direct-acting antiviral (DAA) therapy [3], with around 88,790 (estimated 45% of chronic HCV population) treated since March 2016. Treatment numbers have progressively declined, however, making updated projections of HCV elimination progress essential.

We have previously modelled the Australian HCV epidemic and estimated that all three WHO HCV elimination targets could be met if 14,000 people with HCV are treated each year from 2019, including liver-related mortality among HCV viraemic cases [4]. However, only 11,310 and 8,100 people were treated during 2019 and 2020, respectively, continuing a declining trend since 2016. This trend may not be associated with the COVID-19 pandemic and hence a return to higher treatment levels may not occur. In addition, cured patients, particularly those with cirrhosis, continue to have an elevated risk of liver-related morbidity and mortality, albeit at a lower risk than HCV viraemic individuals [5–7].

We update our modelling estimates annually to track HCV infection and resulting liver disease burden using new surveillance, clinical and treatment data [8]. In particular, estimates for the level of duplicate HCV notifications [9] and a revised estimate for spontaneous clearance [10] have been incorporated, both of which have resulted in a lower estimate of people living with chronic HCV in Australia and resulting liver disease burden. Therefore, here we provide updated estimates for the prevalence of HCV in Australia to the end of 2020 and discuss whether Australia can still meet the WHO elimination targets by 2030 with the current treatment uptake and the ongoing burden of advanced liver disease complications due to HCV infection, despite the rapid treatment uptake in 2016. We also estimated treatment rates required post-2021 for Australia to meet the WHO HCV elimination targets and determined the number of new cases of decompensated cirrhosis (DC), hepatocellular carcinoma (HCC), and liver-related mortality among the HCV viraemic and cured populations in Australia from 2015 to 2030.

### Materials and methods

The model we use for the Australian HCV estimates is based on the Bright model developed by the Center for Disease Analysis (CDA). This model was adapted to reflect Australian settings from a previous model [4] and is updated annually to include data to the end of each year for HCV prevalence, number of diagnoses, and DAA uptake and to capture specific characteristics of Australia’s HCV epidemic.

### Model structure

The model has been described in detail previously [4, 11]. Here we provide a summary focusing on the key features of relevance for this update and analysis. The model is a compartmental difference equation model implemented in Microsoft Excel (Redmond, WA) with the overall Australian population categorized by age, sex, and HCV disease stage (as shown in Fig 1). As described previously, we assume HCV cure following DAA therapy reduces the liver-related mortality rate among people living with DC and HCC by 50%. This is based on recent evidence from HCV linkage studies in NSW, Australia which showed a two to three-fold increase in HCC survival following treatment in the DAA era [12]. The disease progression rate among the cured population is lower compared to the viraemic population (Table 1).

The model incorporated interferon-based (IFN-based) therapy, prior to the introduction of DAA therapy, with SVR rates depending on regimen and genotype [4, 13, 14]. From 2016, we
assumed SVR rates for DAA therapy from clinical studies including disease stage at initiation (Table 1).

Updated estimate of 2015 base prevalence

The model uses the estimated HCV prevalence at the end of 2015 as a calibration target for the model and as a starting point for treatment scenarios. Previously we estimated 227,000 people were living with chronic HCV in Australia at the end of 2015 [4]. We have updated the model to reflect recently available data and to incorporate improved knowledge of the roll-out and impact of DAA therapy on HCV epidemics. To estimate the number of people living with HCV in 2015 we used cumulative notifications and spontaneous clearance, mortality, and migration rate estimates. Recent linkage studies being conducted in the Australian states of New South Wales (NSW) and Victoria estimated that 7 to 11% of notifications were duplicates [9]. Given this evidence and the level of uncertainty in duplication, we assumed 9% (range 7–11%) of all notifications are duplicates. Furthermore, recent evidence from a linked cohort in British Columbia [10] suggests the proportion of HCV diagnoses who were HCV RNA negative is 28% (3% higher than what we used previously). These adjustments combined produce a 12% reduction in the cumulative HCV notifications and a lower overall estimate for the number of people living with HCV in Australia at the end of 2015.

Updated estimates of morbidity and mortality due to HCV infection

To improve our estimates of liver-related mortality in the model, we incorporated a higher risk of developing cirrhosis, DC, HCC, and liver-related mortality among the population with excessive alcohol consumption (defined as > 50g per day). For example, people living with
HCV who have excessive alcohol consumption are 2.3 (95% CI 1.7–3.3) times more likely to develop cirrhosis [15, 16]. We used available progression rates for those with and without excessive alcohol consumption from published literature and the percent of HCV infected people with DC or HCC that have excess alcohol consumption based on hospital admissions for alcohol use disorder from the NSW, Australia linkage study. The study showed the percentage of patients with alcohol use disorder among HCV infected people with DC and HCC increased from 14% to 51% over 2001–2018. We adjusted the percentage of people with alcohol use disorder who do not have DC or HCC in our updated model to match the number of liver-related deaths from the NSW linkage study. This resulted in an estimate of 19% with excessive alcohol consumption.

Table 1. Model inputs and parameter estimates.

| Parameters                                                                 | Value | Reference                                      |
|---------------------------------------------------------------------------|-------|------------------------------------------------|
| Population size and age distribution (1990–2030)                          |       | [4]                                            |
| Total viraemic cases (2015)                                               | 188,690| Revised calculation as described in the main text |
| Newly HCV diagnoses (2020)                                                | 8,110 | [20]                                           |
| Number of people treated                                                  | See below | Updated from [21, 22]                        |
| Disease progression rates                                                 |       |                                                |
| Acute to F0                                                               | 4.4% - 21.8% | [23, 24]                                     |
| F0 to F1                                                                 | 3.4% - 14.3% | [23, 24]                                     |
| F1 to F2                                                                 | 4.5% - 22.4% | [23, 24]                                     |
| F2 to F3                                                                 | 4.7% - 20.0% | [23, 24]                                     |
| F3 to F4                                                                 | 0.24% | [25]                                           |
| F3 to HCC                                                                | 3.0%  | [25]                                           |
| F4 to DC                                                                 | 3.6%  | [7, 25]                                        |
| F4 to HCC                                                                | 20.0% | [5, 24, 26, 27]                                 |
| DC liver-related mortality                                                | 70.7% | [24, 26, 27]                                   |
| HCC liver-related mortality                                               | 16.2% | [24, 26, 27]                                   |
| 1st year                                                                 | 4.4% - 21.8% | [23, 24]                                     |
| Subsequent years                                                          | 3.4% - 14.3% | [23, 24]                                     |
| Reduction in progression rate from F3 to HCC (cured)                      | 77%   | [5]                                            |
| Reduction in progression rate from F4 to DC (cured)                       | 76%   | [6, 7]                                         |
| Reduction in progression rate from F4 to HCC (cured)                      | 77%   | [5]                                            |
| Reduction in liver-related mortality among cured DC and HCC population    | 50%   | [12]                                           |
| Relative risk of having cirrhosis among population with excessive alcohol consumption (>50g per day) | 1.7 – 3.3 | [15, 16]                                     |
| Spontaneously clearance rate                                              | 28%   | [10]                                           |
| Background mortality rate                                                 | 1.76% | [28]                                           |
| SVR rate (F0-F3)                                                          | 95%   | [29–32]                                        |
| SVR rate (F4)                                                             | 90%   |                                                |
| Treatment roll-out scenarios                                              |       |                                                |
| 2015 (interferon + DAA)                                                   | 4,720 | 33,200                                         |
| 2016                                                                      | 4,720 | 33,200                                         |
| 2017                                                                      | 4,720 | 33,200                                         |
| 2018                                                                      | 4,720 | 33,200                                         |
| 2019                                                                      | 4,720 | 33,200                                         |
| 2020                                                                      | 4,720 | 33,200                                         |
| Post-2021                                                                 |       |                                                |

Abbreviations: F0–F4 = Fibrosis stage from F0 to F4; DC = decompensated cirrhosis; HCC = Hepatocellular carcinoma; SVR = Sustained virological response. Note: Pessimistic roll-out: 40% decrease of DAA uptake from 2018; Intermediate roll-out: DAA uptake remains at 2019 level; Optimistic roll-out: Where DAA uptake remains at 2018 level.

https://doi.org/10.1371/journal.pone.0257369.t001
consumption who do not have DC or HCC, which aligns with available data from the separate NSW linkage and Enhancing Treatment of Hepatitis C in Opioid Substitution Settings (ETHOS) studies [17].

Updated DAA treatment data and projection scenarios
The proportion of DAA treatments initiated by patients in each fibrosis stage was estimated using the Real-world Efficacy of Antiviral therapy for Chronic Hepatitis C (REACH-C) [18] and Pharmaceutical Benefits Scheme (PBS) data [19]. From March 2016 to the end of 2020, 88,790 people living with chronic HCV received DAA therapy. Of those, 23–27% were in F0, 23–27% were in F1, 15–17% were in F2, 10% were in stage F3, 20–30% were in stage F4. During 2016–2020, the proportion who received treatment in each disease stage was relatively stable. We assumed treatment disease stage distribution post-2021 remained at the 2020 level with recent evidence of stable treatment uptake in each disease stage throughout 2016–2020.

As in our previous work, we developed three treatment scenarios from the end of 2020 based on the estimated number of DAA therapy initiations from 2016 to 2020. Post-2021 we assumed a pessimistic roll-out corresponding to 40% less people being treated with DAA therapy than for 2019, an intermediate roll-out corresponding to the annual number treated equaling the number in 2020, and an optimistic scenario where the annual number treated increased back to the 2019 level. Table 2 shows the corresponding treatment numbers for Australia. For comparison purposes, we also ran an IFN-based (pre-DAA listing) scenario where the number treated remains at the 2015 level (n = 4,720) and new HCV infections are held constant until 2020.

Calculation of treatment coverage
To calculate treatment coverage on an ongoing basis for tracking towards HCV elimination targets, we considered new infections, cured people, and mortality during the DAA era. The treatment coverage for HCV in a given year was defined as the number of people who have been treated and are still living since the end of 2015 at the end of the year divided by the number of people who have lived with chronic HCV since the end of 2015 (including still living with HCV and those cured) at the end of the previous year.

Model calibration
The detailed methodology used for calibration has been described previously [4]. With the updated notification and treatment data we estimated the 2015 base prevalence at 188,690 people. The model was calibrated to this prevalence and 8,110 new diagnoses at the end of 2020 (with duplicates removed; Table 1, additional model inputs are in S1 Table in S1 File) by calculating the annual HCV incidence using a constant multiplier describing the relative incidence compared to the incidence in 1950.

Generation of results
The Oracle Crystal Ball add-in (Oracle Corp) for Excel software was used to perform 1000 Monte Carlo simulations (using samples from the parameter ranges in Table 1) and estimate 95% confidence intervals (CIs) for the model outputs up to 2030 for each treatment scenario. The final spreadsheet used to produce all the results is available upon reasonable request.

This modelling study used publicly available and reported surveillance data and did not require ethics approval. All data are in an aggregated and de-identified format.
Table 2. The key HCV estimates with treatment roll-out scenarios (best estimate, 95% CI†).

| End of 2015 | Baseline (2015) | Pessimistic treatment scenario | Intermediate treatment scenario | Optimistic treatment scenario |
|-------------|----------------|--------------------------------|---------------------------------|-------------------------------|
| People living with chronic HCV | 188,690 (170,620–203,530) | 60,370 (35,500–81,760) | 48,140 (24,000–69,650) | 19,290 (4,860–44,630) |
| New infections (all) | 5,600 (5,350–6,110) | 1,310 (610–2,080) | 1,010 (210–1,860) | 280 (40–1,300) |
| Chronic HCV prevalence | 0.8% (0.7%-0.9%) | 0.2% (0.1%-0.3%) | 0.2% (0.1%-0.3%) | 0.1% (0.0%-0.2%) |
| Fibrosis§ | F0 | 52,600 (40,430–70,140) | 8,610 (2,100–20,040) | 6,030 (560–17,410) | 750 (130–10,940) |
| | F1 | 64,670 (55,650–72,300) | 16,160 (5,760–30,050) | 12,910 (2,690–26,780) | 5,080 (50–18,760) |
| | F2 | 28,100 (25,120–30,480) | 9,150 (3,630–14,400) | 7,280 (1,790–12,510) | 8,990 (8–7,870) |
| | F3 | 25,840 (15,000–37,590) | 15,760 (7,270–24,070) | 13,800 (5,660–21,760) | 1,970 (1,700–16,160) |
| | F4 | 14,970 (8,650–23,170) | 9,280 (1,710–16,100) | 7,090 (1,170–13,770) | 1,630 (480–8,080) |
| Decompensated cirrhosis | 1,300 (640–2,560) | 650 (20–1,760) | 430 (4–1,470) | 40 (3–820) |
| HCC§ | 670 (370–1,320) | 430 (50–1,060) | 340 (30–930) | 100 (10–610) |
| New Decompensated cirrhosis cases | Viraemic | 420 (250–680) | 250 (20–480) | 180 (4–410) | 20 (2–230) |
| | Viraemic + cured | 430 (260–700) | 410 (140–680) | 360 (130–620) | 230 (130–480) |
| New HCC cases | Viraemic | 540 (310–870) | 330 (50–590) | 240 (20–510) | 40 (8–300) |
| | Viraemic + cured | 550 (310–880) | 520 (200–840) | 460 (180–770) | 290 (160–610) |
| Annual liver-related mortality | Viraemic | 730 (410–1,200) | 420 (40–850) | 310 (20–720) | 50 (10–440) |
| | Viraemic + cured | 740 (410–1,220) | 650 (210–1,140) | 550 (200–1,030) | 330 (180–790) |
| Cumulative cases over 2016–2030 | Baseline | 73,420 (68,930–82,540) | 48,650 (41,340–58,180) | 47,110 (39,310–56,990) | 43,330 (35,700–54,080) |
| New infections (all) | 73,420 (68,930–82,540) | 48,650 (41,340–58,180) | 47,110 (39,310–56,990) | 43,330 (35,700–54,080) |
| New Decompensated cirrhosis cases | Viraemic | 8,320 (4,650–13,110) | 3,030 (480–6,430) | 2,670 (380–6,050) | 1,800 (370–5,160) |
| | Viraemic + cured | 9,040 (5,200–14,310) | 4,830 (1,740–8,750) | 4,540 (1,670–8,450) | 3,820 (1,730–7,750) |
| New HCC cases | (Continued) |
At the end of 2015, an estimated 188,690 people were living with chronic HCV. Of those, 81% were diagnosed with HCV and 22% (n = 33,200) of those diagnosed received treatment during 2016. Among people living with chronic HCV in 2015, 28% were in stage F0, 34% were in stage F1, 15% were in stage F2, 14% were in stage F3, and 9% were in stage F4 (cirrhosis) (Table 2). In 2015, an estimated 740 (95% CI: 410–1,220) people living with chronic HCV died with HCV-related liver disease.

At end 2020, an estimated 117,810 (95% CI: 96,510–135,640) people were living with chronic HCV. Of those, 77% (n = 90,560; 95% CI: 57,010–131,500) were diagnosed with HCV and 8% (n = 8,100) of people living with chronic HCV and diagnosed at end 2019 (n = 95,870) received treatment in 2020. Around 88,790 people living with chronic HCV in Australia received DAA therapy during 2016–2020, equating to approximately 45% treatment coverage by the end of 2020. Among people living with chronic HCV at end 2019 and received treatment during 2020, uptake varied by disease stage: 7% (n = 2,150) of people in stage F0, 5% (n = 2,150) in F1, 7% (n = 1,380) in F2, 4% (n = 810) in F3, and 23% (n = 1,480) in F4.

### Reductions in HCV prevalence, incidence, and liver-related mortality due to DAA

In Australia, there were substantial reductions in chronic HCV prevalence, new HCV cases per year (incidence), and liver-related mortality in all DAA treatment scenarios (Fig 2). The chronic HCV prevalence decreased to 60,370 (95% CI: 35,000–81,760; 68% reduction) by 2030.
Table 2, Fig 3) in the pessimistic scenario, and to 48,140 (95% CI: 24,000–69,650; 74% reduction) and 19,290 (95% CI: 4,860–44,630; 90% reduction) in intermediate and optimistic scenarios in 2030, respectively. Compared to the incidence in 2015, the HCV incidence in 2030 was 77%, 82%, and 95% lower in the pessimistic, intermediate, and optimistic scenarios, respectively (Fig 3).

The new HCV cases per year (incidence) of DC, HCC and liver-related mortality among the HCV viraemic population decreased rapidly with DAA therapy scale-up due to the
reduction in those remaining viraemic with advanced fibrosis (with liver-related mortality almost eliminated by 2030). In contrast, despite the reduced risk or progression among those with cirrhosis who were cured, the growing population size of people with advanced fibrosis among the cured population meant that DC, HC, and liver-related mortality declined slowly. In the intermediate scenario, there remained an estimated 180 (95% CI: 130–220) new cases of DC, 210 (95% CI: 160–260) new cases of HCC, and 250 (95% CI: 180–310) liver-related mortality among the cured population in 2030. Among the combined viraemic and cured population, the estimated number of liver-related deaths was 650 (95% CI: 210–1,140), 550 (95% CI: 200–1,030), and 330 (95% CI: 180–790) in the pessimistic, intermediate, and optimistic scenarios in 2030, respectively (Fig 2). The estimated liver-related mortality among the combined viraemic and cured population in 2030 is 12%, 25%, and 55% lower compared to 2015, in the pessimistic, intermediate, and optimistic scenarios, respectively (Fig 3). In contrast, the estimated liver-related mortality among the viraemic population in 2030 is 43%, 58%, and 93% lower compared to 2015, in the pessimistic, intermediate, and optimistic scenarios, respectively (Fig 4).

In the intermediate scenario, the model projected that Australia can achieve the WHO HCV elimination incidence and treatment targets by 2032 if the current treatment uptake remains the same (90% reduction in incidence in 2032, and 80% treated in 2030, see Fig 2 and Table 2). The pessimistic scenario will meet the WHO incidence and treatment targets by 2034 (90% reduction in incidence in 2034, and 80% treated in 2032), and the optimistic scenario will meet the WHO incidence and treatment targets by 2030 (90% reduction in incidence in 2030, and 80% treated in 2027). The 65% reduction of liver-related mortality target is only achievable with the optimistic scenario in 2023 when only the viremic population is considered but difficult to achieve when viraemic and cured liver-related deaths are combined (Table 2, Fig 2).

Our sensitivity analysis showed that the year of meeting the WHO HCV mortality target is sensitive to the risk of developing cirrhosis among people living with chronic HCV who have excessive alcohol consumption. The year of meeting the WHO mortality target ranged from 2042 to after 2050 in the intermediate scenario. Our analysis showed that Australia needs to
treat at least 16,790 (post-2021, 107% higher than 2020 level) people living with chronic HCV per year to meet the WHO mortality target by 2030. We also ran the model without excess alcohol consumption which showed that the year the WHO mortality target among viraemic cases is met in 2021 in the intermediate scenario but this target would not be achieved if viraemic and cured cases are considered (S2 Table in S1 File).

Discussion

With the updated mathematical model incorporating complete national datasets on HCV diagnoses and treatment as well as effects of alcohol use disorder, we found that Australia cannot meet the WHO HCV incidence and treatment targets by 2030 if the current treatment uptake remains at the 2020 level. The 28% reduction in treatment uptake in 2020 compared to 2019 is consistent with the decreasing trend in treatment and testing in Australia [33]. Our analysis highlights that Australia needs to treat at least 16,790 (post-2021, 107% higher than 2020 level) people living with chronic HCV per year to meet all WHO targets by 2030.

Our study showed that the ability to meet the 65% reduction in HCV liver-related mortality target depends on how mortality is defined. This is consistent with our previous findings [4] but we have updated the model to include other risk factors that significantly impact mortality post-cure, such as an increased risk of developing cirrhosis among people who have excessive alcohol consumption. We also updated the model to include new data on the proportion of people living with chronic HCV who initiated DAA treatment in each fibrosis stage obtained from the REACH-C study and the Pharmaceutical Benefits Scheme. When HCV liver-related mortality includes people with chronic HCV and those who are cured, the target will be difficult to be met by 2030 even under the optimistic scenario as the increasingly large cured population continues to contribute to HCV-related deaths. Australia is one of the leading countries for the roll-out of DAA therapies providing unrestricted access to people living with HCV, but we have demonstrated that Australia will still find it hard to achieve the WHO HCV mortality target. The increasing trajectory of liver-related mortality prior to the DAA era, due to the ageing chronic HCV population, is a key factor in determining the feasibility of mortality targets with 2015 as the baseline. When HCV liver-related mortality includes only people with chronic HCV, then a 65% reduction would only be achieved under an optimistic treatment scenario. This study, therefore, highlights a need to more clearly define the WHO HCV mortality indicator.

This is an updated study that builds on a previous model [4, 34] by incorporating the ongoing risk of DC and HCC among individuals who have been cured and increased risk among individuals with excessive alcohol consumption. The model used the most up-to-date national datasets, including the total number of people who are treated in 2016–2020, and the relatively higher treatment uptake among those in more advanced liver disease stages. In our model we implicitly assumed testing rates were sufficient for the appropriate number of people to be treated and that harm reduction programs remained at the 2016 level, to focus on the impact of treatment as prevention strategies. Another Australian modelling study by Scott et al. [35] suggested that the WHO incidence target of a 90% reduction would not be reached if the current testing rate remains the same. Our results also suggest that WHO HCV incidence and treatment coverage targets will no longer be met by 2030 under the intermediate scenario (annual number treated equaling the number in 2020). Both studies highlight the challenge of maintaining or reaching the high treatment rate required to achieve the WHO HCV elimination targets. Around 88,790 people living with chronic HCV in Australia received DAA therapy in 2016–2020, equating to approximately 45% treatment coverage by the end of 2020. The
treatment coverage of 80% will be achieved by 2030 with the intermediate scenario and by 2027 with the optimistic scenario.

People living with DC and HCC remain at risk of liver disease and liver-related death. Even with the reduced risk of progression from advanced fibrosis to DC and HCC in those who are cured, many deaths among this relatively large population will continue to occur. The rate of mortality among people who develop advanced liver disease complications is particularly high, especially in those with a history of alcohol use disorder [36]. There are additional strategies that could further reduce mortality beyond the impact of DAA therapy. First, alcohol abstinence among those with advanced fibrosis, even if cured, is likely to reduce the risk of DC and HCC and thus liver-related mortality. Second, regular HCC screening among those with advanced fibrosis should increase early detection of HCC and the uptake of curative HCC management. Third, enhanced access to liver transplantation could provide further benefits. For example, people with ongoing alcohol or drug use have generally been de-prioritized for transplantation.

There are several limitations in this study. The model did not specifically include DAA uptake among at-risk populations such as people who inject drugs and prisoners. However, evidence suggests that DAA uptake among people who inject drugs has been even higher than the broader chronic HCV population (47% among people with drug dependence or current injecting compared to 38% among the broader population) [37, 38]. The prevalence of heavy alcohol consumption was based on hospital admissions for alcohol use disorder from an Australian HCV data linkage study. This might underestimate the true number of people with heavy alcohol consumption and is therefore conservative. The model also did not track the reinfection of people who cleared the virus. Instead, the population who cleared the virus will return to the susceptible pool and have the same risk of HCV reinfection as for primary HCV. Again, this should be conservative, as the incidence of HCV reinfection is generally lower than primary infection. In the previous study, we showed that the model is quite sensitive to the level of mortality reduction post-cure among those with DC and HCC. We used a 50% reduction from the linkage study of HBV patients and conducted a sensitivity analysis varying the mortality reduction from 0% to 80%. In the current study, we used results from ongoing linkage studies in Australia which showed a two to three-fold increase in HCC survival following treatment in the DAA era. Further iterations of HCV elimination progress and target feasibility will be required as DAA treatment is updated and further information is gathered on several model parameters.

There are several important clinical and policy implications of this study. This study has demonstrated that it will be very difficult to reach the WHO HCV elimination targets in Australia under the current treatment scenarios. This is particularly concerning given the reductions in HCV testing and treatment during the COVID-19 pandemic which will further delay the attainment of elimination targets [39]. As such, it will be important to consider the implementation of evidence-based interventions that have been shown to enhance HCV testing [40, 41], including medical chart reminders [40], dried-blood-spot testing [42], point-of-care HCV antibody testing [43–46], point-of-care HCV RNA testing [47–49], and reflex HCV RNA testing [50–52]. It will also be essential to implement strategies that have been demonstrated to increase treatment, including patient navigation or care coordination [53–55] and integration of HCV care into drug treatment settings [56, 57]. Scale-up of evidence-based interventions to enhance HCV testing and treatment will be critical to achieve the increases in treatment uptake required to meet the WHO viral hepatitis elimination targets. The information from this study is important for both national and international policies and viral hepatitis strategies to inform target setting and facilitate the development of feasible actions and workplans to achieve the WHO viral hepatitis elimination targets nationally and globally.
In conclusion, our analysis demonstrated that meeting WHO HCV elimination targets will be difficult to achieve if the current treatment uptake remains at the 2020 level. Our study highlights that treatment uptake level needs to be increased by 107% to meet all WHO targets by 2030. Furthermore, our study highlighted that even if a large population of people with viraemic HCV are cured there will still be high levels of liver disease, DC, HCC and liver-related mortality. The liver-related mortality targets by 2030 will be difficult to achieve if the mortality indicator includes people who are cured due to the ongoing risk of DC and HCC among this population, and increased risk of progression post-cure among those with alcohol use disorder.

Supporting information
S1 File.
(DOCX)

Acknowledgments
JAK produced results, interpretation of findings, and wrote the manuscript; GJD lead the study, providing oversight in the design, implementation, interpretation of findings, and manuscript writing; BH, MA, and HV assisted in data collection and editing the manuscript; JG assisted in providing oversight in the design, interpretation of finding, and editing the manuscript; RG assisted in providing oversight in the design, implementation, interpretation of findings, and editing the manuscript; RTG lead the study, providing oversight in the design, implementation, interpretation of findings, and manuscript writing. We acknowledge NSW Health, Homie Razavi, Chris Estes, and Australian HCV Diagnosis and Care Cascade Reference group for their input.

Author Contributions
Conceptualization: Jisoo A. Kwon, Gregory J. Dore, Jason Grebely, Rebecca Guy, Richard T. Gray.
Data curation: Jisoo A. Kwon, Behzad Hajarizadeh, Maryam Alavi, Heather Valerio.
Investigation: Richard T. Gray.
Methodology: Jisoo A. Kwon, Gregory J. Dore, Maryam Alavi, Richard T. Gray.
Visualization: Rebecca Guy.
Writing – original draft: Jisoo A. Kwon, Gregory J. Dore, Richard T. Gray.
Writing – review & editing: Behzad Hajarizadeh, Maryam Alavi, Heather Valerio, Jason Grebely, Rebecca Guy.

References
1. World Health Organization (WHO). Interim guidance for country validation of viral hepatitis elimination. Geneva, Switzerland: World Health Organization; 2021.
2. WHO. Global health sector strategy on viral hepatitis 2016–2021: towards ending viral hepatitis. 2016.
3. Hajarizadeh B, Grebely J, Martinello M, Matthews GV, Lloyd AR, Dore GJ. Hepatitis C treatment as prevention: evidence, feasibility, and challenges. The lancet Gastroenterology & hepatology. 2016; 1 (4):317–27.
4. Kwon JA, Dore GJ, Grebely J, Hajarizadeh B, Guy R, Cunningham EB, et al. Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study. Journal of viral hepatitis. 2019; 26(1):83–92. https://doi.org/10.1111/jvh.13013 PMID: 30267593
5. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013; 158(5 Pt 1):329–37. https://doi.org/10.7326/0003-4819-158-5-201305050-00005 PMID: 23460056

6. Di Marco V, Calvaruso V, Ferraro D, Bavetta MG, Cabibbo G, Conte E, et al. Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension. Gastroenterology. 2016; 151(1):130–9 e2. https://doi.org/10.1053/j.gastro.2016.03.036 PMID: 27039970

7. Nahon P, Bourcier V, Layese R, Audureau E, Cagniot C, Marcellin P, et al. Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. Gastroenterology. 2017; 152(1):142–56 e2. https://doi.org/10.1053/j.gastro.2016.09.009 PMID: 27641509

8. The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2018. UNSW Sydney; 2018.

9. NSW Ministry of Health. Guides and caveats for interpreting infectious diseases data 2017 [Available from: https://www.health.nsw.gov.au/Infectious/diseases/Pages/guides-and-caveats.aspx.]

10. Bartlett SR, Yu A, Chapinal N, Rossi C, Butt Z, Wong S, et al. The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: Impact of direct acting antivirals. Liver international: official journal of the International Association for the Study of the Liver. 2019; 39(12):2261–72. https://doi.org/10.1111/liv.14227 PMID: 3144846

11. Polaris Observatory HCV. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. The lancet Gastroenterology & hepatology. 2017; 2(3):161–76. https://doi.org/10.1016/S2468-1253(16)30181-9 PMID: 28404132

12. He S, Alavi M, Lockhart I, Law MG, Grebely J, et al. Improved survival following hepatitis C-related hepatocellular carcinoma diagnosis in the era of direct-acting antiviral therapy in New South Wales, Australia JHEP Reports (under review). 2020.

13. Gidding HF, Law MG, Amin J, Ostapowicz G, Weltman M, Macdonald GA, et al. Hepatitis C treatment outcomes in Australian clinics. The Medical journal of Australia. 2012; 196(10):633–7. https://doi.org/10.5694/mja12.10014 PMID: 22676878

14. Roberts SK, Weltman MD, Crawford DH, McCaughan GW, Sievert W, Cheng WS, et al. Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial. Hepatology. 2009; 50(4):1045–55. https://doi.org/10.1002/hep.23130 PMID: 19676125

15. Hutchinson SJ, Bird SM, Goldberg DJ. Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. Clin Gastroenterol Hepatol. 2005; 3(11):1150–9. https://doi.org/10.1016/s1542-3565(05)00407-6 PMID: 16271348

16. Peters MG, Terrail NA. Alcohol use and hepatitis C. Hepatology. 2002; 36(Suppl 1):S220–5. https://doi.org/10.1053/jhep.2002.36811 PMID: 12407597

17. Valerio H, Alavi M, Silk D, Treloar C, Milat A, Dunlop A, et al. PS-070-Uptake of testing, linkage to care, and treatment for hepatitis C infection among people who inject drugs in Australia: The ETHOS Engage study. Journal of Hepatology 2019; 70: e42.

18. The Kirby Institute. Real world efficacy of antiviral therapy in chronic hepatitis C in Australia (Issue 2). The Kirby Institute, UNSW Sydney; July 2018.

19. The Kirby Institute. Monitoring hepatitis C treatment uptake in Australia (Issue 11). The Kirby Institute, UNSW Sydney; 2021.

20. The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia. Annual Surveillance Report UNSW; 2016 [Available from: https://kirby.unsw.edu.au/report/annual-surveillance-report-hiv-viral-hepatitis-stis-2016.

21. Hajarizadeh B, Grebely J, Matthews GV, Martiniello M, Dore GJ. Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia. Journal of viral hepatitis. 2017. https://doi.org/10.1111/1345 PMID: 27197716

22. Dore GJ, Hajarizadeh B. Elimination of Hepatitis C Virus in Australia: Laying the Foundation. Infect Dis Clin North Am. 2018; 32(2):269–79. https://doi.org/10.1016/j.idc.2018.02.006 PMID: 29778255

23. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. Aids. 2008; 22(15):1979–91. https://doi.org/10.1097/QAD.0b013e32830ed401 PMID: 18784461

24. Harris RJ, Thomas B, Griffiths J, Costella A, Chapman R, Ramsay M, et al. Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios. Journal of hepatology. 2014; 61(3):530–7. https://doi.org/10.1016/j.jhep.2014.05.008 PMID: 24824282
25. Altekruse SF, Henley SJ, Cucinelli JE, McGlynn KA. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol. 2014; 109(4):542–53. https://doi.org/10.1038/ajg.2014.11 PMID: 24513805

26. Bernfort L, Sennfalt K, Reichard O. Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden. Scand J Infect Dis. 2006; 38(6–7):497–505. https://doi.org/10.1080/0036554050032803 PMID: 16798701

27. Ries L, Young G, Keel G, Eisner M, Lin Y, Horner M. SEER survival monograph: Cancer survival among adults: U.S. SEER program, 1988–2001, patient and tumor characteristics. Bethesda, MD: National Cancer Institute; 2007.

28. Shkolnikov V, Barbieri M, Wilmoth J. The Human Mortality Database (HMD) [Available from: http://www.mortality.org/.

29. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Subramanian GM, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NSSA inhibitor ledipasvir or the NSSB non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology. 2014; 146(3):736–43 e1. https://doi.org/10.1053/j.gastro.2013.11.007 PMID: 24262278

30. Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014; 383(9916):515–23. https://doi.org/10.1016/S0140-6736(13)62121-2 PMID: 24209977

31. Poordad F, Lawitz E, Kowdle KV, Cohen DE, Podsadecki T, Siggelkow S, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. The New England journal of medicine. 2013; 368(1):45–53. https://doi.org/10.1056/NEJMoa1208809 PMID: 23281979

32. Field JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and Velpatasvir for HCV Genotypes 1, 2, 4, 5, and 6 Infection. The New England journal of medicine. 2013; 368(24):2599–607. https://doi.org/10.1056/NEJMoa1315980 PMID: 26571066

33. WHO Collaborating Centre for Viral Hepatitis, Doherty Institute for Infection and Immunity. Impacts of COVID-19 on BBVSTI testing, care and treatment: Medicare data analysis. Doherty Institute; 2020.

34. Sievert W, Razavi H, Estes C, Thompsen AJ, Zekry A, Roberts SK, et al. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia. Journal of gastroenterology and hepatology. 2014; 29 Suppl 1:1–9. https://doi.org/10.1111/jgh.12677 PMID: 25055928

35. Scott N, Sacks-Davis R, Wade AJ, Stoove M, Pedrana A, Doyle JS, et al. Australia needs to increase testing to achieve hepatitis C elimination. The Medical journal of Australia. 2020; 212(8):365–70. https://doi.org/10.5694/mja2.50544 PMID: 32167586

36. Hutchinson SJ, Bird SM, Goldberg DJ. Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland. Hepatology. 2005; 42(3):711–23. https://doi.org/10.1002/hep.20836 PMID: 16116637

37. Valerio H, Alavi M, Law M, Tillakeratne S, Amin J, Janjua N, et al. High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia: A population-based study. Under Review.

38. Kirby Institute. Hepatitis C elimination in NSW: monitoring and evaluation report, 2019. Sydney: Kirby Institute, UNSW Sydney; 2019.

39. Blach S, Kondili LA, Aghemo A, Cai Z, Dugan E, Estes C, et al. Impact of COVID-19 on global HCV elimination efforts. Journal of hepatology. 2021; 74(1):31–6. https://doi.org/10.1016/j.jhep.2020.07.042 PMID: 32773222

40. Zhou K, Fitzpatrick T, Walsh N, Kim JY, Chou R, Lackey M, et al. Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses. Lancet Infect Dis. 2016; 16(12):1409–22. https://doi.org/10.1016/S1473-3099(16)30208-0 PMID: 27615026

41. Bajis S, Dore GJ, Hajarizadeh B, Cunningham EB, Maher L, Grebely J. Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review. Int J Drug Policy. 2017; 47:34–46. https://doi.org/10.1016/j.drugpo.2017.07.002 PMID: 28797498

42. Coats JT, Dillon JF. The effect of introducing point-of-care or dried blood spot analysis on the uptake of hepatitis C virus testing in high-risk populations: A systematic review of the literature. Int J Drug Policy. 2015; 26(11):1050–5. https://doi.org/10.1016/j.drugpo.2015.05.001 PMID: 26118799

43. Sahajian F, Bailly F, Vanheems P, Fantino B, Vannier-Niltenberg C, Fabry J, et al. A randomized trial of viral hepatitis prevention among underprivileged people in the Lyon area of France. J Public Health (Oxf). 2011; 33(2):182–92.
44. Bottero J, Boyd A, Gozlan J, Carrat F, Nau J, Pauti MD, et al. Simultaneous Human Immunodeficiency Virus-Hepatitis B-Hepatitis C Point-of-Care Tests Improve Outcomes in Linkage-to-Care: Results of a Randomized Control Trial in Persons Without Healthcare Coverage. Open Forum Infect Dis. 2015; 2(4): ofv162. https://doi.org/10.1093/ofid/ofv162 PMID: 26668814

45. Frimpong JA, Shiu-Yee K, Tross S, D’Aunno T, Perlman DC, Strauss SM, et al. Bundling Rapid Human Immunodeficiency Virus and Hepatitis C Virus Testing to Increase Receipt of Test Results: A Randomized Trial. Med Care. 2020; 58(5):445–52. https://doi.org/10.1097/MLR.0000000000001311 PMID: 32040038

46. Bartholomew TS, Nakamura N, Metsch LR, Tookes HE. Syringe services program (SSP) operational changes during the COVID-19 global outbreak. Int J Drug Policy. 2020; 83:102821. https://doi.org/10.1016/j.drugpo.2020.102821 PMID: 32591222

47. Davies L. Elimination of hepatitis C in a remand prison using a rapid point of care driven test and treat pathway. EASL, The Digital International Liver Congress 2020.

48. Ustianowski A. Rapid test & treat programme successfully facilitating hepatitis C micro-elimination in a women’s prison. EASL, The Digital International Liver Congress 20202020.

49. Japaridze M, Ruiz R, Khonelidze I, Butsashvili M, Alkazashvili M, Shilton S. APPROACHES TO PROVIDING HEPATITIS C VIREMIA TESTING TO PEOPLE WHO INJECT DRUGS IN GEORGIA; HEAD START (HEPATITIS ELIMINATION THROUGH ACCESS TO DIAGNOSTICS) GEORGIA. The International Network on Hepatitis in Substance Users (INHSU); Le Westin, Montréal, Canada 2019.

50. Hirsch AA, Lawrence RH, Kern E, Falck-Ytter Y, Shumaker DT, Watts B. Implementation and evaluation of a multicomponent quality improvement intervention to improve efficiency of hepatitis C screening and diagnosis. Jt Comm J Qual Patient Saf. 2014; 40(8):351–7. https://doi.org/10.1016/s1553-7250(14)40046-1 PMID: 25208440

51. Abe CM, Aguwa M, Zhao M, Sullivan J, Porsa E, Nijhawan AE. Hepatitis C Virus Infection in the Dallas County Jail: Implications for Screening, Prevention, and Linkage to Care. Public Health Rep. 2019; 134 (6):626–33. https://doi.org/10.1177/0033354919874081 PMID: 31530099

52. Averhoff F, Lazarus JV, Sergeenko D, Colombo M, Gamkrelidze A, Tsertsvadze T, et al. Excellence in viral hepatitis elimination—Lessons from Georgia. Journal of hepatology. 2019; 71(4):645–7. https://doi.org/10.1016/j.jhep.2019.06.026 PMID: 31356831

53. Deming R, Ford MM, Moore MS, Lim S, Perumalswami P, Weiss J, et al. Evaluation of a hepatitis C clinical care coordination programme’s effect on treatment initiation and cure: A surveillance-based propensity score matching approach. Journal of viral hepatitis. 2018; 25(11):1236–43. https://doi.org/10.1111/jvh.12929 PMID: 29757491

54. Ford MM, Johnson N, Desai P, Rude E, Laraque F. From Care to Cure: Demonstrating a Model of Clinical Patient Navigation for Hepatitis C Care and Treatment in High-Need Patients. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2017; 64(5):865–91.

55. Hsiang JC, Sinnaswami P, Lee MY, Zhang MM, Quek KE, Tan KH, et al. Point-of-care hepatitis C screening with direct access referral to improve linkage of care among people with substance misuse: a pilot randomised study. Singapore Med J. 2020. https://doi.org/10.11622/smedj.20201116 PMID: 32729928

56. Cassell M. IMPROVED LINKAGE TO HEPATITIS C ASSESSMENT AND TREATMENT WITHIN COMMUNITY DRUG SERVICES THROUGH COMBINED HEPATITIS C AND OPIATE SUBSTITUTION TREATMENT PRESCRIPTION APPOINTMENTS. The International Network on Hepatitis in Substance Users (INHSU) Le Westin, Montréal, Canada 2019.

57. Grebely J, Alavi M, Micallef M, Dunlop AJ, Balcomb AC, Phung N, et al. Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study. Addiction. 2016; 111(2):311–9. https://doi.org/10.1111/add.13197 PMID: 26451534